New Pall business unit launches to focus on end-to-end drug manufacturing models
Pall Biotech to focus on enabling drug manufacturers to rapidly transition from pre-clinical to commercial manufacturing.
Pall Corporation has a newly named business unit within the Pall Life Sciences division. The Pall Biotech business unit has been named to reflect an important strategic direction for the company. The update will not impact current or prospective company operations.
“As the lines between the biopharmaceutical and biotechnology sectors continue to merge, our commitment is stronger than ever to develop and deliver end-to-end capabilities with cutting-edge technologies and services. The name Pall Biotech reflects a more focused approach to serving these high-growth market segments,” said Mario Philips, Vice President & General Manager of Pall Biotech. “It also reflects our dedication to reducing costs, while increasing efficiency and quality, for today’s developer of sensitive biologic products, including mAbs, recombinant proteins, viral vaccines, and cell and gene therapies.”
Critical partnerships in the industry and alignment with regulatory agencies will play a key role in improving both the integrated and stand-alone elements of the Pall Biotech total bioprocessing solutions portfolio.
“Pall Biotech does not make drugs—we enable drug manufacturers with rapid transition from pre-clinical to commercial manufacturing,” explained Martin Smith, Chief Technology Officer of Pall Corporation. “In 2018, our Pall Life Sciences division boasts the most complete solutions from drug discovery through delivery with Pall Laboratory for research and discovery, Pall Biotech enabling next-generation manufacturing processes, and Pall Medical for patient delivery.”
Related News
-
News Moderna to buy OriCiro Genomics in USD $85 million deal
Pharmaceutical company Moderna acquires genomics services company OriCiro Genomics, based in Tokyo, Japan, to boost mRNA therapeutics development and manufacturing portfolio. -
News New year, new prices: at least 350 drugs in USA to see price increases in January
Drugmakers such as Pfizer, GSK, BMS, AstraZeneca, and Sanofi are planning to raise prices for at least 350 unique drugs in the United States in early January. -
Sponsored Content 2023 Pharma Trend Outlook: Innovation, Resilience, and Pharma 4.0
Download our 2023 Pharma Trends Outlook report to discover the trends set to shape the pharmaceutical landscape in the new year, with expert opinions and insight from across the pharmaceutical value chain. -
News Strategic partnership between AstraZeneca and G42 Healthcare to increase pharmaceutical manufacturing in Abu Dhabi
A comprehensive, long-term partnership agreement between AstraZeneca and G42 Healthcare is set to enhance local drug manufacturing in Abu Dhabi, UAE, and bolster pharmaceutical manufacturing innovation within the country. -
News CordenPharma joins sustainability initiative to achieve Net Zero
The CDMO has joined the environmental initiative looking to align private sector companies with those aims upheld by the Paris Agreement to reduce global warming. -
News AstraZeneca acquires Neogene in shift into cell-based cancer therapies
AstraZeneca has recently announced that it will be acquiring the biotechnology company Neogene Therapeutics as part of it’s expansion into cell-based cancer treatments.
-
News A mRNA universal flu vaccine is in early stages of development
Researchers from the University of Pennsylvania have developed a universal flu vaccine using nanoparticle encapsulated mRNA. -
News Biovac partnership to increase African vaccine manufacturing capabilities
South African biopharma company Biovac signs a partnership deal with the International Vaccine Institute to develop and manufacture an oral cholera vaccine for both the African and global market.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance